Teva registry study finds 23% of young adults with TD symptoms formally diagnosed

• Teva flagged new real-world data from its ongoing IMPACT-TD Registry showing a large diagnostic gap for tardive dyskinesia in adults with mood disorders, with results already presented at the 2026 American Psychiatric Association Annual Meeting.
• The analysis found that many younger adults reported meaningful day-to-day and psychological burden from involuntary movements despite relatively milder symptom severity.
• Formal diagnosis rates were lowest in younger age groups, pointing to missed identification in routine clinical care.
• The registry also showed patients often wait years between first recognition of abnormal movements and a confirmed diagnosis, a pattern that could limit access to treatment and support.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605180800OMX_____CNEWS_EN_GNW1001182040_en) on May 18, 2026, and is solely responsible for the information contained therein.